A Multicenter, Randomized, Phase 2 Study to Assess the Feasibility, Safety and Efficacy of OTO-104 Given by Intratympanic Administration in Subjects at Risk for Ototoxicity From Cisplatin Chemotherapy Regimens in the Treatment of Cancer
Latest Information Update: 26 May 2025
At a glance
- Drugs Dexamethasone (Primary)
- Indications Hearing loss
- Focus Therapeutic Use
- Sponsors Otonomy [CEASED]
Most Recent Events
- 21 May 2025 Results assessing feasibility, safety, and trends of the efficacy of intratympanic injections of sustained-exposure dexamethasone thermosensitive gel (OTO-104) for otoprotection, published in the Pediatric Blood and Cancer.
- 14 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Sep 2017.
- 13 Sep 2017 Status changed from recruiting to discontinued according to an Otonomy media release.